Latest Aqueous humour Stories
DIEPENBEEK, Belgium, April 8, 2013 /PRNewswire/ -- Amakem NV, a kinase platform company focusing on ophthalmology, today announces it has sponsored a new Chair of Ophthalmology Translational Research at the Catholic University Leuven (KU Leuven), Belgium. The Chair has been established by the University and Amakem to drive further translational research into the prevention of diseases leading to impaired vision or blindness with a special emphasis on glaucoma. It will...
DIEPENBEEK, Belgium, April 8, 2013 /PRNewswire/ -- Amakem NV, a kinase platform company focusing on ophthalmology, today announces it has sponsored a new Chair of Ophthalmology Translational Research at the Catholic University Leuven (KU Leuven), Belgium. The Chair has been established by the University and Amakem to drive further translational research into the prevention of diseases leading to impaired vision or blindness with a special emphasis on glaucoma. It will...
A six-year collaboration between two faculty members of Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has yielded new insight regarding the regulation of intraocular pressure (IOP) in glaucoma – an irreversible blinding disease that causes progressive visual impairment due to optic nerve damage and is the leading cause of blindness worldwide. The key finding by associate professors of ophthalmology Richard K. Lee, M.D., Ph.D., and Sanjoy Bhattacharya,...
Toxic Anterior Segment Syndrome (TASS) is a rare but sight threatening complication of cataract surgery. It occurs mainly within 48 hours after the Surgery. (PRWEB) December 21, 2011 Online Eye Info. The American Academy of Ophthalmology announced today a partnership with the U.S. Food and Drug Administration on a program to track Toxic Anterior Segment Syndrome (TASS) which is a rare but sight threatening complication of cataract surgery . The Academy will help to create an online...
(Ivanhoe Newswire) -- Glaucoma "“ the second leading cause of blindness in the world "“ is now thought to run in families. A team of investigators from Vanderbilt University and the University of Florida offer an eye opening finding where they have just identified a novel candidate gene for the most frequent form of the eye disorder, primary open angle glaucoma (POAG). The findings present new insights into glaucoma pathology, which could lead to targeted treatment...
Glaucoma "“ a leading cause of vision loss and blindness worldwide "“ runs in families. A team of investigators from Vanderbilt University and the University of Florida has identified a new candidate gene for the most common form of the eye disorder, primary open angle glaucoma (POAG).The findings, reported Feb. 17 in the open-access journal PLoS Genetics, offer novel insights into glaucoma pathology and could lead to targeted treatment strategies.Elevated pressure inside the eye is a...
An eye under pressure appears to express a unique set of proteins that physicians hope will one day help them better diagnose and treat glaucoma.Glaucoma, the second leading cause of blindness worldwide, tends to progress silently until decreased vision indicates trouble, said Dr. Kathryn Bollinger, Medical College of Georgia clinician-scientist specializing in glaucoma.But inside fluid-filled eyeballs, a changing protein profile "“ 30 with significant increases and 17 with significant...
SOUTH SAN FRANCISCO, Calif., April 5 /PRNewswire/ -- Altheos, Inc., a privately held early-stage biopharmaceutical company, announced today that it has completed a $20 million Series A financing led by Bay City Capital. New investors Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital also joined the round. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor Altheos licensed from Japanese pharmaceutical company Asahi Kasei...
US-based biopharmaceutical company Inspire Pharmaceuticals has announced that the standard 30-day review period by the FDA relating to the company's investigational new drug application for INS117548 ophthalmic solution for the treatment of glaucoma has concluded and clinical testing can proceed. Inspire is currently targeting the initiation of a Phase I clinical trial by the end of 2008 to evaluate the tolerability and efficacy of this product candidate in subjects with early stage glaucoma...
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that the standard 30-day review period by the U.S. Food and Drug Administration (FDA) relating to Inspire's Investigational New Drug Application (IND) for INS117548 Ophthalmic Solution for the treatment of glaucoma has concluded and clinical testing can proceed. Inspire is currently targeting the initiation of a Phase 1 clinical trial by the end of 2008 to evaluate the tolerability and efficacy of this product candidate in...
